港股異動 | 信達生物漲5.6% 去年總收入大增74.1%至42.61億元
格隆匯3月30日丨信達生物漲5.6%,報30.15港元,總市值442億港元。信達生物公吿,截至2021年12月31日止年度,公司總收入為人民幣42.61億元,同比增加74.1%。截至2021年12月31日止年度的產品收入達人民幣40.01億元,同比增長69%。主導產品達伯舒(信迪利單抗注射液)作為抗程序性細胞死亡蛋白1(PD-1)市場的領先品牌,在銷售收入及銷量上均保持強勁增長。同時,持續擴充的商業化產品中其他產品也促進了產品收入的強勁增長,收入貢獻佔截至2021年12月31日止年度產品總收入的約30%。產品銷售的毛利率為88.6%,較截至2020年12月31日止年度的84.9%上升3.7%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.